Previous studies have reported that preoperative neutrophil-to-lymphocyte (NLR) and platelet-tolymphocyte ratios were prognostic for various types of cancers. The aim of this study was to investigate the predictive utilities of preoperative peripheral blood counts in patients with gastrointestinal stromal tumors (GISTs). We enrolled 510 consecutive, previously untreated patients who underwent surgery for primary, localized GISTs. The relationship between recurrence-free survival and outcome variables was assessed by univariate and multivariate analyses, while the clinicopathologic relevance of NLR was determined using the Chi-square test. A preoperative NLR ≥2 was associated with poor prognosis in patients undergoing surgeries for primary, localized GISTs. It was an independent predictor only in patients classified as National Institutes of Health high risk but not in the entire population. Preoperative NLR is a feasible and reproducible peripheral biomarker that helps identify patients for intensive adjuvant therapy and frequent surveillance.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors arising from the gastrointestinal tract, with an estimated annual incidence of 10-20 in 1,000,000 reported in western countries [1] . They are presumed to originate from the interstitial cells of Cajal, which are pace-makers that regulate the peristalsis of the gastrointestinal tract [2] . Surgical resection is a potentially curative therapy for GIST, but outcomes remain poor due to the high frequency of recurrence [3] . The discovery of oncogenic gain-of-function kinase mutations in c-kit and PDGFRα [4, 5] , combined with the observed effect of novel small molecule tyrosine kinase inhibitors (TKIs) [6] , revolutionarily transformed the oncologic outcomes of GIST [7, 8] . Based on the fact that the adjuvant imatinib remarkably decreases the risk of relapse after surgical resection of localized GIST [9, 10] , its use is highly recommended, especially for those with high risk of recurrence [11] . In such setting, accurate estimation of the risk of recurrence following surgery is increasingly important for identifying patients who require more frequent surveillance and intensive adjuvant therapy.
Over the past decade, more evidence has suggested that cancerrelated inflammation plays a crucial role in tumor development.
Attention has been paid to its clinical use as a prognostic biomarker and therapeutic target [12] [13] [14] . While inflammation involves many cells and cytokines both systemically and locally, measuring the systemic inflammatory response (SIR) would be a more useful clinical tool. Neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios are two widely available biomarkers reflecting the degree of SIR and have been reported to be associated with prognoses for various tumor types [15] [16] [17] [18] [19] [20] [21] . Recently, several studies have examined the association of NLR and PLR with outcomes in GIST, but the sample size was small and results were controversial [22] [23] [24] [25] . In the present study, we analyzed the preoperative peripheral blood counts in 510 patients with primary, localized GIST who underwent operations in Zhongshan Hospital, seeking to determine their predictive abilities and correlation with the established prognostic factors.
Materials and Methods

Study population
We retrospectively reviewed 574 consecutive, previously untreated patients who underwent curative surgical resection for primary GIST in Zhongshan Hospital between June 2006 and June 2014. Resectability of the disease was preoperatively assessed by computed tomography (CT) or magnetic resonance imaging, and patients with locally advanced or metastases were excluded from this study. To ensure the representativeness of the normal baseline blood cell counts, patients were excluded if they were younger than 18 years, had a synchronous non-GIST malignancy, had emergency surgeries, had coexistent hematological disorders or chronic inflammatory disorders, or had received any medications that could affect the blood test results. Finally, 510 GIST patients were regarded as eligible for analysis, including 448 without adjuvant imatinib and 62 with adjuvant imatinib. Our study was approved by the Zhongshan Hospital Ethics Committee and informed consent was obtained from each patient.
Peripheral blood counts
Preoperative blood samples used for analysis were collected on the day of admission to eliminate any inflammatory effects stemming from sequential preoperative examinations. The duration between admission and surgery is usually 1 or 2 days, at most 3 days. None of the patients had clinical signs of infection or other inflammatory conditions at the time of blood sampling. Blood NLR was calculated as absolute neutrophil count (number of neutrophils/μl) divided by absolute lymphocyte count (number of lymphocytes/μl) and blood PLR was calculated as absolute platelet count (number of platelets/μl) divided by absolute lymphocyte count (number of lymphocytes/μl). Threshold values used to dichotomize different blood counts were defined with respect to the sample median, which was 2 for NLR and 127 for PLR.
Data collection and statistical analysis
Data including demographic details, histopathologic diagnosis (tumor size, site, mitotic index, etc.), preoperative blood counts, adjuvant use of imatinib, site, and date of recurrence were collected from our electronic patient records. All patients were followed up regularly through CT until June 2015 or until death. Follow-ups occurred every 6 months for the first 3 years from surgery and every year thereafter.
All statistical analyses were performed using SPSS 19.0 software. Recurrence-free survival (RFS) was defined as the interval from surgical resection to radiologic evidence of recurrence and survival curves were computed by the Kaplan-Meier product limit method with intergroup difference compared by log-rank test. Univariate and multivariate analyses of the association between RFS and the study variables were performed using Cox proportional hazard regression models. Significant prognostic factors identified by univariate analysis were further evaluated by the multivariate analysis. The association between dichotomized NLR and clinicopathologic characteristics was analyzed using the Chisquare test. P-value < 0.05 was considered statistically significant.
Results
Patient characteristics
The subject group was composed of 243 males and 267 females, with a median age of 59 years (range 19-85 years) at diagnosis. The most frequent site of occurrence was the stomach (66.5%), followed by the small intestine (27.8%) and other sites (5.7%). The median tumor size was 5 cm (range 0.6-30.5 cm) and the majority of patients (69.8%) had a mitotic rate of five or fewer mitoses per 50 high power field (HPF). In all, 87.6% of the tumors showed a spindle cell phenotype, 7.3% showed an epitheloid phenotype, and 5.1% showed a mixed phenotype. According to National Institutes of Health (NIH) risk-stratification scores [26] , 49 (9.6%) were classified in the very low-risk group, 200 (39.2%) in the low-risk group, 79 (15.5%) in the intermediate-risk group, and 182 (35.7%) in the high-risk group. There were 62 (12.2%) patients receiving adjuvant imatinib following surgery in this series. Table 1 shows the baseline demographic, clinicopathologic, and treatment characteristics of the (Fig. 1A-C) . However, multivariate analyses indicated that only tumor site, tumor size, and mitotic rate were independent prognostic factors for RFS ( Table 2) . On the other hand, univariate analyses of patients receiving adjuvant imatinib showed that none of the preoperative blood cell counts were associated with RFS ( Table 3) .
Predictive abilities of peripheral blood counts within NIH criteria
Because some peripheral blood counts correlated with RFS in primary, resected GIST without adjuvant imatinib, we further analyzed their prognostic significance within NIH criteria. Considering that there were only two recurrences in subgroups classified as very low, low, and intermediate recurrence risk, RFS analysis was performed only in the NIH high-risk subgroup (Fig. 1D) . For the univariate analysis, tumor size (≤7 cm vs. >7 cm), mitotic rate (≤10/50 HPF vs. >10/50 HPF), and preoperative NLR (<2 vs. ≥2) were associated with RFS ( Fig. 2A-C and Table 4 ). Elevated NLR (≥2) indicated shorter RFS in this patient subgroup, with a 65.2% 5-year RFS in the high NLR group compared to 82.1% in the low group (P = 0.034) (Fig. 2D) .
Multivariate analyses showed that the three above-mentioned parameters were all independent prognostic factors for RFS ( Table 4) .
Discussion
Estimation of recurrence risk is not only important in providing information on postoperative survival but also in determining adjuvant treatment, especially in this era of adjuvant TKI therapy. Presently, several risk-stratification schemes have been developed and validated based on postresection pathologic parameters including tumor size, tumor location, mitotic count, and tumor rupture. However, there is discrepancy between risk-stratification schemes predicted recurrence rates and the observed recurrence rate. In addition, patients classified as high risk by these schemes, our potential pool for further treatment and surveillance, vary greatly from each other in prognosis. Therefore, developing new criteria or supplementing current stratification systems with novel parameters is critical to improve predictive accuracy. Over the past decade, it has been increasingly recognized that cancer progression is dependent not only on tumor-related characteristics but also on host immune and inflammatory response [27, 28] . Cancerassociated inflammation is shown to promote tumor progression and metastases via suppressing antitumor immunity and is closely related to various stages of tumor development. It has thus been postulated that inflammation based prognostic scores, such as NLR and PLR, could provide useful information for prognosis. Recently, numerous studies have supported the use of NLR as a prognostic factor in patients with several carcinomas, including colorectal, hepatocellular, gastric, pancreatic, ovarian, and endometrial malignancies [13, 14, [18] [19] [20] [21] .
To the best of our knowledge, there are few investigations to date evaluating the prognostic abilities of NLR and PLR in GIST and their usefulness remains controversial. We herein carried out RFS analysis in 510 patients undergoing surgical treatment for primary, localized GIST to evaluate the prognostic impact of preoperative blood counts, specifically NLR and PLR. Our results showed that elevated NLR was associated with increased recurrence in the entire group consisting of different risk populations but was not independently predictive. This was consistent with the studies reported by Perez and Feng, which also demonstrated that NLR and PLR (not included in the study by Perez) were not independent prognostic factors on multivariate analyses [23, 25] . A recent study by Racz et al. [22] indicated that only PLR but not NLR was prognostic in GIST based on univariate analyses. The lack of statistical significance is possibly due to its small patient cohort with a relatively low event rate. However, Goh et al. [24] found that both NLR and PLR were independent prognostic factors for GIST on univariate and multivariate analyses. This difference was possibly attributed to a different cut-off value and a dissimilar population distribution.
Inclusion of patients with low or moderate risk of recurrence and exclusion of patients with adjuvant imatinib are likely to result in a more favorable tumor profile in terms of size, location, and mitotic rate. To minimize selection bias and survival advantage by imatinib, we performed survival analyses in subgroups divided by adjuvant imatinib and NIH criteria. Subgroup analyses revealed that high NLR, not PLR, was an independent predictor for poor RFS within the NIH high-risk category. However, in patients receiving adjuvant imatinib, peripheral blood counts did not show any prognostic significance. We suppose that changes of peripheral blood counts before and after adjuvant imatinib may be more meaningful in this subgroup, which was not performed in our study due to incomplete set of blood values after adjuvant imatinib.
Despite their prognostic potential for clinical application, the precise mechanisms for the association between elevated NLR and poor prognosis remain to be elucidated. One possible explanation is that NLR indicates the balance between pro-tumor inflammatory response and antitumor immunity [29] [30] [31] . Lymphocytes, on one hand, inhibit the proliferative and metastatic ability of cancer cells via inducing cytotoxic cell death and cytokine production [32, 33] . Neutrophils, on the other hand, have been shown to induce tumor proliferation, invasion, and vascularization by releasing proangiogenic chemokines and other factors [34] [35] [36] . In addition, it was reported that increased neutrophils could even inhibit the immune system via suppressing the cytolytic activity of immune cells such as lymphocytes and nature killer cells [37, 38] . Therefore, elevated NLR indicates a relative lymphocytopenia and neutrophilia, tipping the balance in favor of pro-tumor inflammatory status, which is associated with poor oncological outcome. The cost-effectiveness, preoperative availability, and relatively good performance of NLR make it a useful clinical biomarker. It not only provides us with prognostic information prior to surgery but also identifies patients for adjuvant therapy and frequent surveillance after surgery, especially for this paradigm. However, there were several limitations in our study. First, it was a retrospective, single-center investigation with patients treated over a relatively long period of time. Prospective and appropriately designed studies are needed to minimize the chance of bias. Second, the cut-off values of our study and previous ones were not consistent. Thus, a uniform and reliable cut-off value should be identified for further investigation and clinical application. Peripheral blood counts, especially NLR, represent useful parameters in prognosticating primary GIST following surgeries and incorporation of NLR into NIH criteria may further identify patients who need intensive adjuvant imatinib and frequent surveillance. However, this needs to be corroborated in prospective and appropriately designed studies with larger sample size.
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